中山屁眼有疙瘩(中山上大便为什么会流血) (今日更新中)

WASHINGTON, D.C. – Miles Taylor, a former chief of staff at the Department of Homeland Security, revealed Wednesday that he's the anonymous senior Trump administration official who wrote a scathing book last year that criticizes the president."Donald Trump is a man without character. It’s why I wrote “A Warning”...and it’s why me & my colleagues have spoken out against him (in our own names) for months," Taylor announced on Twitter. "It’s time for everyone to step out of the shadows."Read Taylor's full statement here.Taylor's anonymously written book “A Warning” paints a chilling portrait of President Donald Trump as cruel, inept and a danger to the nation he was elected to lead, The Washington Post reports.The book’s description on Amazon says it was meant to motivate readers to “consider how we judge our nation's leaders, and illuminate the consequences of re-electing a commander in chief unfit for the role.”The book was published in November 2019, more than a year after The New York Times published a bombshell op-ed essay by the same anonymous author.In the op-ed, the author claimed to be among a group of people in the White House who were working to keep Trump’s reckless impulses in check for the good of the country.As “part of the resistance inside the Trump administration,” the article’s author said the group believed Trump acts in a manner that is “detrimental to the health of our democracy” and that they vowed to do what they can to “preserve our democratic institutions.”The book and article have been criticized by the president and members of his administration. It also sparked a long guessing game in Washington to figure out who the author was.The Times reports that Taylor resigned from DHS in June 2019 and then went public with his criticism of Trump this past summer. He has since endorsed former Vice President Joe Biden for president. 1890

WASHINGTON, D.C. -- For Steve and Linda Trilling, it’s a trying time: balancing fears of the coronavirus and awaiting the chance for Steve to get a kidney transplant.“Everything got pushed back,” he said.Steve is fortunate, though – he found a match in a living donor. The problem is that the coronavirus caused most hospitals to temporarily stop transplant surgeries. Steve’s wife, Linda, who is a nurse, understands why.“I want him to be off a dialysis. I want him to be healthy again,” she said. “I also want it to be in a safe atmosphere.”The issue goes beyond just waiting for surgeries to resume.Right now, more than 112,000 people are awaiting an organ transplant in the U.S., according to the Health Resources and Services Administration. While most will get an organ from a living donor, approximately one-third, 33%, of all organs used in transplants come from donors who died in motor vehicle accidents. When widespread lockdowns kept people at home and off the road this past spring, those particular organ donations dropped, as did others.David Klassen is with the United Network for Organ Sharing, a nonprofit which manages the nation’s transplantation system through a contract with the federal government.“Starting in about mid-March, organ donation really plummeted fairly abruptly and there is an approximately 50% decrease in the number of organ donors over the course of about two weeks,” Klassen said.Safety measures instituted since COVID-19 emerged include testing organ donors. Klassen remains hopeful the transplant system will begin to return to normal.“Right now, actually, the system is increasing the numbers of transplants and really things are getting fairly close back toward what we saw prior to the pandemic,” he said.However, that may also depend on where you live. Record numbers of coronavirus cases are emerging in states across the South and West, which is straining hospital resources. Just this past week, one of the largest hospital systems in Miami placed some transplant surgeries on hold.For Steve and Linda Trilling, there’s hope his dialysis may become a thing of the past.“It's been a ride, you know, trying to get myself as healthy as I can for when everything happens,” he said.He has a potential transplant surgery date set for later this summer.“We are so blessed, so blessed, that we are, that we have a donor, that we have a goal,” Linda said. “So, that is, I think, my biggest thing, is having him off this lifeline.”“Just trying to get back to normal,” Steve added.It is a normalcy that’s been missing for them far longer than for most. For more information on organ transplants or to become a donor, click here. 2677

WASHINGTON, D.C. – Two different doses of a thyroid medication are being recalled because they're not potent enough.The Food and Drug Administration announced Thursday that Acella Pharmaceuticals is voluntarily recalling one lot of 15-milligram and one lot of 120-milligram NP Thyroid?, Thyroid Tablets.The products may have as low as 87% of the labeled amount of levothyroxine, which is used to treat hypothyroidism (an underactive thyroid), according to the FDA.The company’s risk statement says patients being treated for hypothyroidism who receive sub potent NP Thyroid may experience symptoms of hypothyroidism, including fatigue, increased sensitivity to cold, constipation, dry skin, puffy face, hair loss, slow heart rate, depression, swelling of the thyroid gland and/or unexplained weight gain or difficulty losing weight.“There is reasonable risk of serious injury in newborn infants or pregnant women with hypothyroidism including early miscarriage, fetal hyperthyroidism, and/or impairments to fetal neural and skeletal development,” wrote Acella. “In elderly patients and patients with underlying cardiac disease toxic cardiac manifestations of hyperthyroidism may occur, such as cardiac pain, palpitations or cardiac arrhythmia.”So far, Acella says it has received four reports of "adverse events" for these lot numbers, possibly related to the recall.The products subject to recall are packed in 100-count bottles. Their lot numbers are M327E19-1 and M328F19-3. And their expiration dates are Oct. 2020 and November 2020.The products were distributed nationwide to Acella’s direct accounts, including wholesalers, pharmacies, and health care offices.“Acella is proactively notifying its wholesalers by email and phone to discontinue distribution of the two above referenced lots being recalled and is arranging for return of all recalled products,” wrote the company.Anyone who is currently taking NP Thyroid from the lots being recalled should not discontinue use without contacting their health care provider for further guidance and/or a replacement prescription, according to Acella.Anyone with questions about the recall can email Acella at recall@acellapharma.com or contact a representative at 1-888-280-2044.Click here for more information. 2272

We now have VIDEO of that @RoyalAirForce reconnaissance flight over #iceberg #A68a. There are some mighty fissures, and the sea around the berg is littered with bits and bobs. Watchout South Georgia! ???? Read more: https://t.co/0hJP5fDdJ5 pic.twitter.com/MOWUWMuwZg— Jonathan Amos (@BBCAmos) December 8, 2020 323

Watching your dog get old is hard. You see the pain in their eyes when they can't get into the car or run after the ball.Veterinarians across the U.S. say it's not just old age, but arthritis that's causing your dog pain, and a new drug trial is working to make your furry companion feel better.One of the clinics testing the new drug is Paradise Animal Hospital in Catonsville, Maryland. Dr. Cheryl Burke says she to qualify for the trial, dogs have to have obvious signs of arthritis and cannot have cancer. At the clinic, they conduct blood tests, x-rays and a physical exam.Hannah, a blonde chow mix, came in for the procedure."She has a lot of trouble getting up and when she goes to walk up and down the stairs, she stares, like can I do this? Can I do this? Breaks my heart when I see that," Hannah's mom, Donna Foster said.Foster found out from a friend this clinic was conducting the trial and thought she'd take a chance, "I mean she's fourteen years old and basically she's really healthy so if I can keep her for another 20 years, I know that's not realistic but I will and I want her to have a quality of life."The trial was created in San Diego, by Animal Cell Therapies, and uses canine stem cells to grow cartilage in the joint, so the dog has more cushion when he/she walks or runs."Stem cells are the body's primitive precursor cells and we all have them, and when we're born, there's a huge population of them in our umbilical cord," Dr. Burke said.The stem cells adapt to the needs around them, so they could turn cancerous, something Dr. Burke and pet parents don't want. That's why dogs go through several tests (for free) before they can qualify.The clinic is doing the entire trial for free, to get FDA approval, so other pet parents can one day buy the drug.Part of the study requires that the test be double blind, meaning no one, even Dr. Burke can see which drug is given to the dog.Each dog undergoes the same procedure. Then pet parents come back for a one month, three month and six month check up to see how the dog is progressing.If the study is approved any dog who didn't get the drug will get it for free."If it's approved, it could be a few years, before it's on the market but it could be wonderful," Dr. Burke said.There is no ballpark figure as to how much the drug may cost, but dog lovers are hopeful it could help their furry friend have a longer, better life. 2431

来源：资阳报